Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

BACKGROUND AND AIMS: This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an α4β7-integrin inhibitor, and anti-tumour necrosis factor-α [anti-TNFα] agents in biologic-naïve ulcerative colitis [UC] and Crohn’s disease [CD] patients. METHODS: This was a 24-month ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Bressler, Brian, Yarur, Andres, Silverberg, Mark S, Bassel, Marielle, Bellaguarda, Emanuelle, Fourment, Chris, Gatopoulou, Anthie, Karatzas, Pantelis, Kopylov, Uri, Michalopoulos, George, Michopoulos, Spyridon, Navaneethan, Udayakumar, Rubin, David T, Siffledeen, Jesse, Singh, Andrew, Soufleris, Konstantinos, Stein, Dara, Demuth, Dirk, Mantzaris, Gerassimos J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495488/
https://www.ncbi.nlm.nih.gov/pubmed/33786600
http://dx.doi.org/10.1093/ecco-jcc/jjab058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495488/
https://www.ncbi.nlm.nih.gov/pubmed/33786600
http://dx.doi.org/10.1093/ecco-jcc/jjab058

Ejemplares similares